Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Construction in Progress: 2018-2023

Historic Construction in Progress for China SXT Pharmaceuticals (SXTC) over the last 6 years, with Mar 2023 value amounting to $349,390.

  • China SXT Pharmaceuticals' Construction in Progress fell 3.77% to $349,390 in Q1 2023 from the same period last year, while for Mar 2023 it was $349,390, marking a year-over-year decrease of 3.77%. This contributed to the annual value of $349,390 for FY2023, which is 3.77% down from last year.
  • Per China SXT Pharmaceuticals' latest filing, its Construction in Progress stood at $349,390 for FY2023, which was down 3.77% from $363,078 recorded in FY2022.
  • In the past 5 years, China SXT Pharmaceuticals' Construction in Progress registered a high of $649,235 during FY2019, and its lowest value of $328,372 during FY2020.
  • Its 3-year average for Construction in Progress is $356,027, with a median of $355,614 in 2021.
  • Per our database at Business Quant, China SXT Pharmaceuticals' Construction in Progress crashed by 49.42% in 2020 and then grew by 8.30% in 2021.
  • Over the past 5 years, China SXT Pharmaceuticals' Construction in Progress (Yearly) stood at $649,235 in 2019, then plummeted by 49.42% to $328,372 in 2020, then rose by 8.30% to $355,614 in 2021, then rose by 2.10% to $363,078 in 2022, then fell by 3.77% to $349,390 in 2023.